Neubourg Skin Care GmbH has joined the Swedish Avia Pharma family. Neubourg Skin Care GmbH, a German company specializing in foam-based medical skin and foot care products, and Avia Pharma AB, a Swedish pharmaceutical company with a broad healthcare portfolio, both operate in the healthcare and life sciences sector.
While Neubourg focuses primarily on dermatology and podiatry with products like Allpresan, Avia Pharma offers a diverse range including dermatology, allergology, women's health, urology, and OTC products. This acquisition aims to expand Avia Pharma’s product offerings and strengthen its presence, particularly in the DACH region.
Neubourg Skin Care GmbH, based in Greven, Germany, is renowned for its innovative foam-based medical skin and foot care products. Under the leadership of Dr. Thomas Neubourg, who succeeded his father Fritz Neubourg, the company has specialized in pioneering products primarily used in foot care. The company's well-known product lines include Allpresan, Podoexpert, Onyfix, Fußpunkt, Sixtus, and Skincare, employing a workforce of 70. With Avia Pharma AB's acquisition, Stefan Lang becomes the new Managing Director, while Dr. Thomas Neubourg remains as a consultant. The takeover aims to consolidate expertise in skin, foot, and nail care and expand the product portfolio. Despite the management change, the company culture will be preserved, and the Greven site and jobs are expected to remain secure. Future plans include increased collaboration with Avia’s German subsidiary Allergika, offering new opportunities for development and exchange within the group.
Avia Pharma AB, located near Stockholm, Sweden, is a growing company in the marketing and distribution of medical products. Since its inception, Avia Pharma has focused on dermatology, allergology, women's health, urology, and over-the-counter (OTC) products. The acquisition of Neubourg Skin Care GmbH is part of Avia Pharma's strategy to strengthen its presence in the DACH region and expand its product portfolio. With this acquisition, Avia Pharma's annual sales will exceed €53 million. Avia Pharma owns several brands, including Nix, Duroferon, and Allergika, the latter offering cosmetic and medical products specifically designed for individuals with skin diseases and problems. The acquisition of Neubourg Skin Care not only signifies Avia Pharma's growth but also its commitment to enhancing its offerings in skin, foot, and nail care through strategic partnerships and integration of expertise. The collaboration with Allergika, acquired in 2022, highlights the synergies and potential for innovative developments within the group.
ConAlliance, a leading advisory firm in the M&A sector, boasts extensive expertise in supporting company sales and acquisitions in the healthcare sector, with over 150 successful mandates since its founding. ConAlliance focuses exclusively on the global healthcare and life sciences industry, distinguishing itself with deep industry knowledge and tailored advisory services.
ConAlliance also excels in medical and dermatological care products and healthcare solutions that improve patient quality of life. The specialist teams at ConAlliance combine traditional investment banking skills with specific, detailed expertise in healthcare niches. This unique combination of industry insight and financial expertise enables ConAlliance to provide strategically valuable support to clients in dermatology, allergology, women's health, urology, and OTC products.
www.conalliance.com